

DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

September 17, 2020
MO HealthNet

Join Webex Meeting

Meeting number (access code): 133 166 6935

Meeting password: juP6XQPZg36

Join from a video system or application

Dial 1331666935@stateofmo.webex.com

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

Meeting Documents

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 – 10:35	DUR Update	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions – New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
---------------	---	------------

11:00 – 11:45	Clinical Edits Discussion, Public Hearing and Decision will be held for each edit. <ul style="list-style-type: none">i. Botulinum Toxinii. Elagolixiii. Emsamiv. Equetrov. Fintepla - <i>NEW</i>vi. Immunoglobulins (IVIG and SCIG) - <i>NEW</i>vii. Lambert-Eaton Myasthenic Syndrome (LEMS)viii. Narcolepsy Inhibitorsix. Nuedexta - <i>NEW</i>x. Oxandrinxi. Palforzia - <i>NEW</i>xii. Psychotropic Medications Polypharmacyxiii. Ranexaxiv. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)xv. Selective Serotonin Reuptake Inhibitors (SSRI)xvi. Transthyretin-Mediated Amyloidosis (ATTR)xvii. Uplizna - <i>NEW</i>	Josh Moore
---------------	--	------------

- xviii. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors - *NEW*
- xix. Xcopri - *NEW*
- xx. Zometa

11:45 – 1:00

Preferred Drug List (PDL)

Josh Moore

Discussion, Public Hearing and Decision will be held for each edit.

- i. ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations
- ii. ACE-Inhibitors/CCB Combinations
- iii. ADHD – Amphetamine, Short-Acting
- iv. ADHD – Amphetamine, Long-Acting
- v. ADHD – Methylphenidate, Short-Acting
- vi. ADHD – Methylphenidate, Long-Acting
- vii. ADHD – Non-Stimulants
- viii. Anticoagulants
- ix. Anticonvulsants, Rescue Agents - *NEW*
- x. Antiplatelets
- xi. ARBs and ARBs/Diuretic Combinations
- xii. ARBs/CCB Combinations
- xiii. Beta Blockers and Beta Blockers/Diuretic Combinations
- xiv. CCBs, Dihydropyridines
- xv. CCBs, Non-Dihydropyridines
- xvi. Direct Renin Inhibitors and Combinations
- xvii. Dry Eye Disease
- xviii. Homozygous Familial Hypercholesterolemia (HFHC)
- xix. Niacin Derivatives
- xx. PAH – Endothelin Receptor Antagonists (ETRAAs)
- xxi. PAH – PDE5 Inhibitors and SGC Stimulators
- xxii. PAH – Prostacyclins, Inhaled
- xxiii. PAH – Prostacyclins, IV/SQ
- xxiv. PAH – Prostacyclins, Oral
- xxv. Proton Pump Inhibitors
- xxvi. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors
- xxvii. Statins and Statin Combinations
- xxviii. Sympatholytics
- xxix. Triglyceride Lowering Agents

1:00 – 1:15

LUNCH

1:15 – 1:30

Program Utilization Information – Conduent Update

Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

1:30 – 1:50

Other Business

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

NEXT MEETING: December 17, 2020
Department of Natural Resources
1101 Riverside Dr., Jefferson City, MO 65101
Lacharette/Nightingale Rooms